{"gene":"PHOSPHO1","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":2004,"finding":"Human PHOSPHO1 exhibits high specific phosphatase activity toward phosphoethanolamine (PEA) and phosphocholine (PCho), with apparent Km values of 3.0 µM for PEA and 11.4 µM for PCho, optimal activity at pH 6.7, and strict Mg2+-dependence, establishing these as its natural substrates and providing a mechanism for inorganic phosphate generation in mineralizing cells.","method":"In vitro enzymatic assay with recombinant PHOSPHO1, substrate kinetics, pH and metal ion dependence studies","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic reconstitution with recombinant protein and full kinetic characterization","pmids":["15175005"],"is_preprint":false},{"year":2003,"finding":"Comparative modeling of human PHOSPHO1 based on phosphoserine phosphatase (PSP) crystal structure identified a catalytic Mg2+-binding site coordinated by three conserved Asp residues (Asp32, Asp34, Asp203) and revealed that PHOSPHO1 belongs to a novel subgroup within the HAD superfamily distinct from PSPs, with Asp43 and Asp123 proposed to confer substrate specificity.","method":"Comparative homology modeling based on Methanococcus jannaschii PSP crystal structure; sequence conservation analysis","journal":"Protein engineering","confidence":"Medium","confidence_rationale":"Tier 1 structural modeling but without experimental mutagenesis validation in same paper; later validated by mutagenesis in PMID 16054448","pmids":["14983068"],"is_preprint":false},{"year":2005,"finding":"Mutagenesis of Asp32 and Asp203 abolished PHOSPHO1 phosphatase activity, confirming HAD superfamily membership and catalytic mechanism; Asp43 and Asp123 mutations impaired substrate hydrolysis, demonstrating their role in substrate binding. PHOSPHO2, despite 42% sequence identity, preferentially hydrolyzes pyridoxal-5-phosphate rather than PEA or PCho.","method":"Site-directed mutagenesis of active-site residues; in vitro enzymatic assay with recombinant proteins","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — direct active-site mutagenesis with enzymatic activity readout","pmids":["16054448"],"is_preprint":false},{"year":2004,"finding":"PHOSPHO1 protein is localized by immunohistochemistry specifically to sites of active mineralization in bone and cartilage: osteoid layer of periosteum, forming surfaces of growing osteons, newly formed osteocytes, early hypertrophic chondrocytes of growth plate, and mineralizing surfaces of trabecular bone; absent from non-mineralizing soft tissues.","method":"Immunohistochemistry with affinity-purified antibody; RT-PCR in osteoblast cell lines","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 3 — localization by IHC with functional-context correlation, single lab","pmids":["15050893"],"is_preprint":false},{"year":2006,"finding":"PHOSPHO1 is present within matrix vesicles (MVs) isolated from growth plate chondrocytes as confirmed by immunoblotting, and its expression is upregulated in MVs from chondrocytes induced to differentiate, mirroring TNAP activity upregulation; its developmental expression in chick precedes mineralization onset, consistent with an initiating role.","method":"Immunoblotting of isolated MVs; whole-mount in situ hybridization; qPCR during chondrocyte differentiation","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 — direct MV fractionation with immunoblot confirmation plus developmental expression timing, replicated across studies","pmids":["16837257"],"is_preprint":false},{"year":2007,"finding":"PHOSPHO1 is functionally active within matrix vesicles: sonicated (but not intact) MVs from TNAP-deficient osteoblasts exhibit PEA hydrolase activity attributable to PHOSPHO1, and pharmacological inhibitors of PHOSPHO1 (lansoprazole, SCH202676) reduce MV-mediated mineralization by 56.8% and 70.7%, respectively.","method":"Enzyme activity assay in sonicated MVs; high-throughput screening for inhibitors; MV calcification assay in TNAP-null background","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 — enzymatic activity in MV fractions plus pharmacological inhibition with functional mineralization readout","pmids":["17227223"],"is_preprint":false},{"year":2010,"finding":"Phospho1-/- mice display growth plate abnormalities, spontaneous fractures, bowed long bones, osteomalacia, and scoliosis; Phospho1-/- chondrocyte-derived MVs show reduced mineralizing ability; plasma PPi is elevated. Transgenic TNAP overexpression normalizes PPi but does not rescue the bone phenotype, indicating PHOSPHO1 has a nonredundant, TNAP-independent role in initiating skeletal mineralization. Double ablation of PHOSPHO1 and TNAP completely abolishes skeletal mineralization and causes perinatal lethality.","method":"Phospho1-/- knockout mouse; TNAP transgenic overexpression in Phospho1-/- background; double Phospho1/Alpl knockout; primary chondrocyte MV calcification assay; plasma PPi measurement","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 — genetic epistasis with double KO, rescue experiment, and in vitro MV assay; replicated across multiple labs","pmids":["20684022"],"is_preprint":false},{"year":2010,"finding":"PHOSPHO1 deficiency in MVs reduces ATP hydrolysis kinetics secondarily via reduction in TNAP levels within PHOSPHO1-deficient MVs; kinetic analysis establishes TNAP as the primary enzyme hydrolyzing ATP and PPi within the MV compartment, while PHOSPHO1 affects MV phosphosubstrate hydrolysis indirectly through regulation of TNAP levels.","method":"Kinetic substrate hydrolysis assays (ATP, ADP, PPi) on isolated MVs from WT, TNAP-/-, NPP1-/-, and PHOSPHO1-deficient osteoblasts","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinetic reconstitution with genetically defined MV fractions","pmids":["19874193"],"is_preprint":false},{"year":2010,"finding":"In vivo inhibition of PHOSPHO1 with lansoprazole completely prevented mineralization of chick limb long bones, and the talpid3 chick mutant (defective hedgehog signaling, absent endochondral mineralization) lacked Phospho1 and Tnap expression, linking hedgehog-regulated chondrocyte differentiation to PHOSPHO1-mediated endochondral mineralization.","method":"Lansoprazole pharmacological inhibition in chick embryo in vivo; micromass cultures with PHOSPHO1 inhibitor; talpid3 mutant expression analysis; whole-mount in situ hybridization","journal":"Bone","confidence":"High","confidence_rationale":"Tier 1–2 — pharmacological inhibition in vivo plus mutant model with mechanistic pathway context","pmids":["20053388"],"is_preprint":false},{"year":2013,"finding":"PHOSPHO1 is expressed and upregulated in mineralizing vascular smooth muscle cells (VSMCs); Phospho1-/- VSMCs fail to mineralize in vitro; pharmacological inhibition of PHOSPHO1 (MLS-0263839) reduces VSMC calcification to ~42% of control, and combined PHOSPHO1 + TNAP inhibition reduces it to ~21%, demonstrating PHOSPHO1 plays a critical initiating role in vascular smooth muscle cell calcification.","method":"Phospho1-/- VSMC cultures; PHOSPHO1-specific inhibitors identified by HTS; calcification assay; dual inhibitor experiment","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus pharmacological inhibition with quantitative calcification readout","pmids":["22887744"],"is_preprint":false},{"year":2014,"finding":"Phospho1-/- mice have elevated plasma osteopontin (OPN) with increased proportion of phosphorylated OPN (p-OPN) in skeleton as shown by LC-MS/MS; genetic ablation of Spp1 (OPN) in Phospho1-/- mice ameliorates scoliosis and long bone defects and corrects mineralization in vitro, identifying p-OPN accumulation (not elevated PPi) as the primary driver of the skeletal phenotype in PHOSPHO1 deficiency.","method":"LC-MS/MS phosphoproteomic analysis; double Phospho1-/-/Spp1-/- knockout mice; histology; in vitro mineralization assay","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 — genetic epistasis double KO with rescue plus LC-MS/MS mechanistic identification","pmids":["24825455"],"is_preprint":false},{"year":2016,"finding":"Double knockout of Phospho1 and Pit1 (phosphate transporter Slc20a1 in chondrocytes) causes more severe skeletal mineralization defects than Phospho1-/- alone; ~80% of double-KO MVs lack mineral vs ~50% for Phospho1-/- and ~25% for WT, measured by atomic force microscopy. Phospho1-/- and double-KO chondrocytes also produce fewer MVs, implicating PHOSPHO1 in MV biogenesis.","method":"Conditional double knockout (Phospho1-/- ; Pit1col2/col2); atomic force microscopy of MVs; bone histomorphometry; biomechanical testing","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 — genetic epistasis double KO with quantitative MV mineral content by AFM","pmids":["26773408"],"is_preprint":false},{"year":2016,"finding":"PTH-induced downregulation of PHOSPHO1 expression in osteoblasts is mediated through the cAMP/PKA signaling pathway, as demonstrated by mimicry with the cAMP agonist forskolin and blockade by PKA inhibitor PKI(5-24); PTH also coordinately suppresses nSMase2 (Smpd3) expression.","method":"Pharmacological pathway dissection (forskolin, PKA inhibitor PKI 5-24) in MC3T3-C14 osteoblast cultures; qPCR; hemi-calvaria organ culture","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis with agonist/antagonist pair identifying cAMP/PKA pathway, single lab","pmids":["27444010"],"is_preprint":false},{"year":2016,"finding":"In Phospho1-/- mice, PHOSPHO1 loss leads to defects in alveolar bone and cellular cementum mineralization (cementoid accumulation, interglobular mineral deposition) with increased OPN deposition; acellular cementum is unaffected, indicating acellular cementum mineralization does not depend on matrix vesicle-mediated (PHOSPHO1-driven) initiation.","method":"Phospho1-/- mouse histology, immunohistochemistry, ISH, microCT; comparison of cellular vs acellular cementum phenotypes","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 — KO with specific phenotypic dissection of two mineralization pathways","pmids":["27016531"],"is_preprint":false},{"year":2017,"finding":"PHOSPHO1 is localized to ameloblast secretory vesicles and the enamel layer; Phospho1-/- mice show reduced enamel mineralization (2-fold reduction in von Kossa silver grain density), decreased phosphate incorporation by EDS, loss of enamel prism architecture, and 1.56-fold increase in prism width, establishing PHOSPHO1 as essential for enamel mineralization.","method":"Immunohistochemistry; Western blot; Phospho1-/- mouse; scanning electron microscopy; EDS elemental analysis; von Kossa staining","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 — KO with multiple orthogonal readouts (SEM, elemental analysis, histology), single lab","pmids":["29089903"],"is_preprint":false},{"year":2020,"finding":"PHOSPHO1 negatively regulates brown adipose tissue (BAT) thermogenesis: Phospho1-/- mice are cold-tolerant with higher thermogenic gene expression in BAT; treatment of mice with the PHOSPHO1 substrate phosphocholine is sufficient to induce cold tolerance and thermogenic gene expression, demonstrating the phosphocholine-to-choline conversion catalyzed by PHOSPHO1 suppresses BAT thermogenesis.","method":"Phospho1-/- mouse; cold tolerance assay; thermogenic gene expression (qPCR); exogenous phosphocholine treatment in vivo","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — KO phenotype plus substrate supplementation rescue experiment, establishing causal substrate-product relationship","pmids":["32554489"],"is_preprint":false},{"year":2020,"finding":"Phospho1-/- mice exhibit improved glucose homeostasis and resistance to high-fat diet-induced obesity and insulin resistance independent of osteocalcin; decreased serum choline in Phospho1-/- mice is normalized by 2% dietary choline supplementation, which also normalizes insulin sensitivity and fat mass, linking PHOSPHO1's phosphocholine hydrolysis activity to systemic choline levels and metabolic regulation.","method":"Phospho1-/- mouse; high-fat diet challenge; metabolomics (serum choline); dietary choline rescue experiment; osteoblast transcriptomics","journal":"BMC biology","confidence":"High","confidence_rationale":"Tier 2 — KO plus dietary rescue experiment linking enzymatic product (choline) to metabolic phenotype","pmids":["33092598"],"is_preprint":false},{"year":2021,"finding":"Proton pump inhibitors (PPIs) directly inhibit PHOSPHO1 enzymatic activity in vitro (IC50 0.73–19.27 µM for different PPIs) and inhibit bone matrix mineralization in primary osteoblast cultures in a concentration-dependent manner; H2 receptor antagonists have no inhibitory effect on PHOSPHO1, suggesting PPI-specific inhibition.","method":"In vitro PHOSPHO1 enzymatic activity assay with PPIs; primary osteoblast mineralization assay","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 1 — direct enzymatic inhibition with IC50 determination plus cell-based mineralization assay, single lab","pmids":["34213594"],"is_preprint":false},{"year":2025,"finding":"PHOSPHO1 (cytosolic protein) exhibits D609-sensitive phosphatidylcholine-phospholipase C (PC-PLC) and phosphatidylethanolamine-phospholipase C (PE-PLC) activities in vitro; overexpression in HEK293 cells increases cellular diacylglycerol (DG) levels; PHOSPHO1 co-sediments and co-localizes with diacylglycerol kinase δ (DGKδ), suggesting PHOSPHO1 supplies DG upstream of DGKδ.","method":"In vitro PLC activity assay; HEK293 overexpression with DG lipid measurement; co-sedimentation and co-localization assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1–2 — in vitro enzymatic activity plus cell-based overexpression and co-localization, single lab, novel finding","pmids":["39992810"],"is_preprint":false},{"year":2008,"finding":"A novel alternatively spliced PHOSPHO1 transcript (PHOSPHO1-3a) was identified, encoding a 292 amino acid protein with a 40 amino acid N-terminal secretory signal while retaining all three HAD superfamily catalytic domains; expression confirmed in human and mouse osteoblast-like cells and chondrogenic ATDC5 cells.","method":"RT-PCR; sequence analysis; in silico signal peptide prediction; cell-line expression profiling","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 — transcript identification without functional validation of the splice variant protein","pmids":["18471996"],"is_preprint":false},{"year":2024,"finding":"Lansoprazole acts as an efficient inhibitor of adipose PHOSPHO1 and produces metabolic benefits (reduced obesity, improved insulin resistance) in a PHOSPHO1-dependent manner; mechanistically, LPZ inhibition of PHOSPHO1 is proposed to suppress conversion of 2-AG-LPA to 2-AG, reducing thermogenic-suppressive cannabinoid receptor signaling.","method":"PHOSPHO1 enzymatic inhibition assay; Phospho1-/- mouse rescue/dependency experiment; adipocyte thermogenesis and mitochondrial respiration assays","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 — enzymatic inhibition confirmed plus PHOSPHO1-dependent in vivo metabolic effects, with proposed substrate mechanism","pmids":["38572109"],"is_preprint":false}],"current_model":"PHOSPHO1 is a Mg2+-dependent HAD-superfamily phosphatase that hydrolyzes phosphoethanolamine and phosphocholine (and exhibits phospholipase C activity on PC/PE) within matrix vesicles to generate inorganic phosphate for the initiation of hydroxyapatite crystal nucleation during skeletal, dental, and vascular mineralization, acting nonredundantly with TNAP (whose role is extravesicular PPi hydrolysis); beyond mineralization, PHOSPHO1's hydrolysis of phosphocholine to choline regulates systemic choline levels and negatively modulates brown adipose tissue thermogenesis and whole-body glucose/fat metabolism."},"narrative":{"teleology":[{"year":2003,"claim":"Structural modeling placed PHOSPHO1 within the HAD superfamily and identified candidate catalytic and substrate-specificity residues, providing the first framework for understanding its enzymatic mechanism.","evidence":"Comparative homology modeling based on Methanococcus jannaschii phosphoserine phosphatase crystal structure","pmids":["14983068"],"confidence":"Medium","gaps":["Model-based predictions lacked experimental mutagenesis validation at time of publication","No crystal structure of PHOSPHO1 itself"]},{"year":2004,"claim":"Kinetic characterization established phosphoethanolamine and phosphocholine as high-affinity natural substrates and defined the strict Mg2+ dependence, answering the fundamental question of what PHOSPHO1 hydrolyzes and how it generates inorganic phosphate.","evidence":"In vitro enzymatic assay with recombinant PHOSPHO1; substrate kinetics, pH and metal ion dependence","pmids":["15175005"],"confidence":"High","gaps":["In vivo substrate utilization within matrix vesicles not yet demonstrated","Product (Pi) contribution to mineral nucleation not directly shown"]},{"year":2004,"claim":"Immunolocalization of PHOSPHO1 protein exclusively to sites of active mineralization in bone and cartilage established the physiological context for its enzymatic activity.","evidence":"Immunohistochemistry with affinity-purified antibody on developing bone and growth plate sections","pmids":["15050893"],"confidence":"Medium","gaps":["Single-lab IHC study","Sub-cellular localization to matrix vesicles not shown in this study"]},{"year":2005,"claim":"Site-directed mutagenesis confirmed the HAD-superfamily catalytic mechanism by showing Asp32 and Asp203 are essential for activity and Asp43/Asp123 mediate substrate binding, validating the earlier structural model.","evidence":"Site-directed mutagenesis of active-site residues with in vitro enzymatic assay","pmids":["16054448"],"confidence":"High","gaps":["No crystal structure to visualize substrate-binding geometry","Distinction between PEA and PCho binding determinants not resolved"]},{"year":2006,"claim":"Direct immunoblot detection of PHOSPHO1 within isolated matrix vesicles and its upregulation during chondrocyte differentiation answered where within the extracellular space PHOSPHO1 acts and linked its expression to the onset of mineralization.","evidence":"MV fractionation with immunoblotting; whole-mount in situ hybridization in developing chick","pmids":["16837257"],"confidence":"High","gaps":["Enzymatic activity within intact MVs not yet demonstrated"]},{"year":2007,"claim":"Demonstrating PHOSPHO1 enzymatic activity within matrix vesicles and showing that pharmacological PHOSPHO1 inhibition reduces MV-mediated mineralization established PHOSPHO1 as a functional mineralizing enzyme inside MVs, not merely a co-localized protein.","evidence":"PEA hydrolase activity in sonicated MVs from TNAP-null osteoblasts; HTS-derived inhibitors (lansoprazole, SCH202676); MV calcification assay","pmids":["17227223"],"confidence":"High","gaps":["Inhibitor specificity for PHOSPHO1 over other phosphatases not fully characterized","Activity measured in sonicated, not intact, MVs"]},{"year":2010,"claim":"Genetic epistasis experiments using Phospho1-/-, TNAP transgenic rescue, and double Phospho1/Alpl knockout mice established that PHOSPHO1 has a nonredundant, TNAP-independent role in initiating mineralization, resolving the long-standing question of whether MV-intrinsic and extravesicular Pi-generating pathways are functionally separable.","evidence":"Phospho1-/- knockout; TNAP transgenic overexpression in Phospho1-/- background; double knockout causing perinatal lethality; MV calcification assay; plasma PPi measurement","pmids":["20684022"],"confidence":"High","gaps":["Precise molecular product (Pi vs membrane lipid remodeling) driving mineral nucleation not distinguished","Human genetic validation lacking"]},{"year":2010,"claim":"In vivo pharmacological inhibition of PHOSPHO1 with lansoprazole completely prevented long bone mineralization in chick embryos, confirming the in vivo requirement and linking hedgehog-regulated chondrocyte differentiation upstream of PHOSPHO1 expression.","evidence":"Lansoprazole treatment of chick embryos; talpid3 hedgehog mutant expression analysis","pmids":["20053388"],"confidence":"High","gaps":["Lansoprazole has off-target effects (proton pump); specificity for PHOSPHO1 in vivo uncertain","Hedgehog–PHOSPHO1 transcriptional pathway intermediates not identified"]},{"year":2014,"claim":"Identification of phosphorylated osteopontin accumulation—rather than elevated PPi—as the primary driver of the Phospho1-/- skeletal phenotype reframed the mechanism: PHOSPHO1 loss permits p-OPN to inhibit mineralization, and genetic removal of Spp1 rescues the defect.","evidence":"LC-MS/MS phosphoproteomics; double Phospho1-/-/Spp1-/- knockout with phenotypic rescue","pmids":["24825455"],"confidence":"High","gaps":["Whether PHOSPHO1 directly dephosphorylates OPN or acts indirectly not resolved","Contribution of PPi versus p-OPN in vivo not fully quantified"]},{"year":2016,"claim":"Genetic interaction between Phospho1 and Pit1 (Slc20a1) revealed that PHOSPHO1-generated Pi and transporter-imported Pi act in parallel to load MVs with mineral; PHOSPHO1 deficiency also reduced MV number, suggesting an additional role in MV biogenesis.","evidence":"Conditional Phospho1-/-;Pit1col2/col2 double knockout; atomic force microscopy of MVs; bone histomorphometry","pmids":["26773408"],"confidence":"High","gaps":["Mechanism by which PHOSPHO1 influences MV biogenesis unknown","Whether MV membrane lipid remodeling links phospholipid hydrolysis to budding not tested"]},{"year":2016,"claim":"Extension of PHOSPHO1's role to dental tissues showed it is required for alveolar bone and cellular cementum mineralization but dispensable for acellular cementum, distinguishing MV-dependent from MV-independent mineralization pathways in teeth.","evidence":"Phospho1-/- mouse dental histology, IHC, ISH, microCT","pmids":["27016531"],"confidence":"Medium","gaps":["Molecular basis for why acellular cementum is PHOSPHO1-independent not explained","Single-lab observation"]},{"year":2020,"claim":"Discovery that Phospho1-/- mice are resistant to diet-induced obesity with improved insulin sensitivity, and that dietary choline supplementation normalizes these phenotypes, established a systemic metabolic function for PHOSPHO1 through its phosphocholine-to-choline conversion activity.","evidence":"Phospho1-/- mouse on high-fat diet; serum metabolomics (choline); dietary choline rescue","pmids":["33092598"],"confidence":"High","gaps":["Tissue source of metabolically relevant PHOSPHO1 activity (bone vs adipose vs other) not delineated","Direct measurement of phosphocholine/choline flux in specific tissues lacking"]},{"year":2020,"claim":"Demonstration that phosphocholine supplementation alone induces cold tolerance and thermogenic gene expression established that PHOSPHO1's substrate phosphocholine, not its product choline, drives brown adipose tissue activation—resolving the directionality of the metabolic effect.","evidence":"Phospho1-/- mouse cold tolerance assay; exogenous phosphocholine treatment in vivo; BAT thermogenic gene expression","pmids":["32554489"],"confidence":"High","gaps":["Direct sensor/receptor for phosphocholine in BAT not identified","Whether this is a cell-autonomous or systemic (endocrine) effect not resolved"]},{"year":2025,"claim":"Identification of phospholipase C activity on phosphatidylcholine and phosphatidylethanolamine, with diacylglycerol production and co-localization with DGKδ, expanded PHOSPHO1's substrate repertoire beyond soluble phosphomonoesters to intact phospholipids.","evidence":"In vitro PLC activity assay; HEK293 overexpression with DG lipid measurement; co-sedimentation and co-localization with DGKδ","pmids":["39992810"],"confidence":"Medium","gaps":["Physiological relevance of PLC activity relative to PEA/PCho hydrolysis not established","Single-lab finding awaiting independent confirmation","Functional consequence of PHOSPHO1-DGKδ coupling not tested in mineralizing cells"]},{"year":null,"claim":"Key unresolved questions include: the crystal structure of PHOSPHO1, the identity of the tissue(s) and cell type(s) responsible for its systemic metabolic effects, whether its phospholipase C activity contributes to MV membrane remodeling and biogenesis, and whether human PHOSPHO1 loss-of-function mutations cause a recognizable skeletal or metabolic disease.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure available","No human genetic disease association from direct evidence","Relative contribution of PEA/PCho hydrolysis versus PLC activity in vivo unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,5,7]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[18]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,5]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[4,5,14]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[18]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,15,16,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,8,11]}],"complexes":[],"partners":["ALPL","SPP1","SLC20A1","DGKD","SMPD3"],"other_free_text":[]},"mechanistic_narrative":"PHOSPHO1 is a Mg2+-dependent HAD-superfamily phosphatase that generates inorganic phosphate within matrix vesicles by hydrolyzing phosphoethanolamine and phosphocholine, thereby initiating hydroxyapatite crystal nucleation during skeletal, dental, and vascular mineralization. Catalytic activity depends on conserved aspartate residues (Asp32, Asp203) for phosphoryl transfer and Asp43/Asp123 for substrate binding [PMID:15175005, PMID:16054448], and PHOSPHO1 operates nonredundantly with tissue-nonspecific alkaline phosphatase (TNAP): double ablation of Phospho1 and Alpl abolishes skeletal mineralization and causes perinatal lethality, whereas TNAP overexpression cannot rescue the Phospho1-null bone phenotype [PMID:20684022]. The mineralization defect in Phospho1-/- mice is driven primarily by accumulation of phosphorylated osteopontin rather than elevated PPi, as genetic removal of Spp1 ameliorates the skeletal phenotype [PMID:24825455]. Beyond mineralization, PHOSPHO1's hydrolysis of phosphocholine to choline regulates systemic choline levels, and its loss confers resistance to diet-induced obesity, improved glucose homeostasis, and enhanced brown adipose tissue thermogenesis—phenotypes reversed by dietary choline supplementation [PMID:33092598, PMID:32554489]."},"prefetch_data":{"uniprot":{"accession":"Q8TCT1","full_name":"Phosphoethanolamine/phosphocholine phosphatase","aliases":[],"length_aa":267,"mass_kda":29.7,"function":"Phosphatase that has a high activity toward phosphoethanolamine (PEA) and phosphocholine (PCho) (PubMed:15175005). Involved in the generation of inorganic phosphate for bone mineralization (By similarity). Acts in a non-redundant manner with PHOSPHO1 in skeletal mineralization: while PHOSPHO1 mediates the initiation of hydroxyapatite crystallization in the matrix vesicles (MVs), ALPL/TNAP catalyzes the spread of hydroxyapatite crystallization in the extracellular matrix (By similarity)","subcellular_location":"Extracellular vesicle","url":"https://www.uniprot.org/uniprotkb/Q8TCT1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PHOSPHO1","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PHOSPHO1","total_profiled":1310},"omim":[],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Actin filaments","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"testis","ntpm":90.6}],"url":"https://www.proteinatlas.org/search/PHOSPHO1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q8TCT1","domains":[{"cath_id":"3.40.50.1000","chopping":"28-267","consensus_level":"high","plddt":95.7896,"start":28,"end":267}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TCT1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TCT1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TCT1-F1-predicted_aligned_error_v6.png","plddt_mean":91.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PHOSPHO1","jax_strain_url":"https://www.jax.org/strain/search?query=PHOSPHO1"},"sequence":{"accession":"Q8TCT1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TCT1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TCT1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TCT1"}},"corpus_meta":[{"pmid":"20684022","id":"PMC_20684022","title":"Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/20684022","citation_count":177,"is_preprint":false},{"pmid":"27148772","id":"PMC_27148772","title":"DNA methylation of loci within ABCG1 and PHOSPHO1 in blood DNA is associated with future type 2 diabetes risk.","date":"2016","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/27148772","citation_count":150,"is_preprint":false},{"pmid":"17227223","id":"PMC_17227223","title":"Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization.","date":"2007","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/17227223","citation_count":142,"is_preprint":false},{"pmid":"15175005","id":"PMC_15175005","title":"Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15175005","citation_count":111,"is_preprint":false},{"pmid":"19874193","id":"PMC_19874193","title":"Kinetic analysis of substrate utilization by native and TNAP-, NPP1-, or PHOSPHO1-deficient matrix vesicles.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19874193","citation_count":109,"is_preprint":false},{"pmid":"15050893","id":"PMC_15050893","title":"PHOSPHO1-A novel phosphatase specifically expressed at sites of mineralisation in bone and cartilage.","date":"2004","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15050893","citation_count":80,"is_preprint":false},{"pmid":"16837257","id":"PMC_16837257","title":"The presence of PHOSPHO1 in matrix vesicles and its developmental expression prior to skeletal mineralization.","date":"2006","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/16837257","citation_count":68,"is_preprint":false},{"pmid":"20053388","id":"PMC_20053388","title":"Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick.","date":"2010","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/20053388","citation_count":54,"is_preprint":false},{"pmid":"22887744","id":"PMC_22887744","title":"Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification.","date":"2013","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/22887744","citation_count":51,"is_preprint":false},{"pmid":"31372594","id":"PMC_31372594","title":"How To Build a Bone: PHOSPHO1, Biomineralization, and Beyond.","date":"2019","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/31372594","citation_count":49,"is_preprint":false},{"pmid":"26773408","id":"PMC_26773408","title":"Skeletal Mineralization Deficits and Impaired Biogenesis and Function of Chondrocyte-Derived Matrix Vesicles in Phospho1(-/-) and Phospho1/Pi t1 Double-Knockout Mice.","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/26773408","citation_count":47,"is_preprint":false},{"pmid":"24825455","id":"PMC_24825455","title":"Ablation of osteopontin improves the skeletal phenotype of phospho1(-/-) mice.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24825455","citation_count":45,"is_preprint":false},{"pmid":"14983068","id":"PMC_14983068","title":"Comparative modelling of human PHOSPHO1 reveals a new group of phosphatases within the haloacid dehalogenase superfamily.","date":"2003","source":"Protein engineering","url":"https://pubmed.ncbi.nlm.nih.gov/14983068","citation_count":40,"is_preprint":false},{"pmid":"16054448","id":"PMC_16054448","title":"Probing the substrate specificities of human PHOSPHO1 and PHOSPHO2.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16054448","citation_count":31,"is_preprint":false},{"pmid":"26457330","id":"PMC_26457330","title":"The Functional co-operativity of Tissue-Nonspecific Alkaline Phosphatase (TNAP) and PHOSPHO1 during initiation of Skeletal Mineralization.","date":"2015","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/26457330","citation_count":27,"is_preprint":false},{"pmid":"32554489","id":"PMC_32554489","title":"Phosphocholine accumulation and PHOSPHO1 depletion promote adipose tissue thermogenesis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32554489","citation_count":20,"is_preprint":false},{"pmid":"27016531","id":"PMC_27016531","title":"Role of PHOSPHO1 in Periodontal Development and Function.","date":"2016","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/27016531","citation_count":19,"is_preprint":false},{"pmid":"28737011","id":"PMC_28737011","title":"A distinctive patchy osteomalacia characterises Phospho1-deficient mice.","date":"2017","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/28737011","citation_count":17,"is_preprint":false},{"pmid":"35900032","id":"PMC_35900032","title":"Increased PHOSPHO1 expression mediates cortical bone mineral density in renal osteodystrophy.","date":"2022","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35900032","citation_count":16,"is_preprint":false},{"pmid":"33092598","id":"PMC_33092598","title":"PHOSPHO1 is a skeletal regulator of insulin resistance and obesity.","date":"2020","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/33092598","citation_count":15,"is_preprint":false},{"pmid":"12464021","id":"PMC_12464021","title":"Chromosomal localization of the chicken and mammalian orthologues of the orphan phosphatase PHOSPHO1 gene.","date":"2002","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12464021","citation_count":14,"is_preprint":false},{"pmid":"27444010","id":"PMC_27444010","title":"The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures.","date":"2016","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/27444010","citation_count":12,"is_preprint":false},{"pmid":"29089903","id":"PMC_29089903","title":"Intravesicular Phosphatase PHOSPHO1 Function in Enamel Mineralization and Prism Formation.","date":"2017","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29089903","citation_count":12,"is_preprint":false},{"pmid":"34213594","id":"PMC_34213594","title":"Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro.","date":"2021","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/34213594","citation_count":12,"is_preprint":false},{"pmid":"36185572","id":"PMC_36185572","title":"Perspective on Dentoalveolar Manifestations Resulting From PHOSPHO1 Loss-of-Function: A Form of Pseudohypophosphatasia?","date":"2022","source":"Frontiers in dental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36185572","citation_count":8,"is_preprint":false},{"pmid":"38572109","id":"PMC_38572109","title":"Repurposing lansoprazole to alleviate metabolic syndrome via PHOSPHO1 inhibition.","date":"2024","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/38572109","citation_count":6,"is_preprint":false},{"pmid":"18471996","id":"PMC_18471996","title":"Identification of a novel splice variant of the haloacid dehalogenase: PHOSPHO1.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18471996","citation_count":6,"is_preprint":false},{"pmid":"39992810","id":"PMC_39992810","title":"Human PHOSPHO1 exhibits phosphatidylcholine- and phosphatidylethanolamine-phospholipase C activities and interacts with diacylglycerol kinase δ.","date":"2025","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/39992810","citation_count":5,"is_preprint":false},{"pmid":"40470038","id":"PMC_40470038","title":"Distinct bone metabolic networks identified in Phospho1-/- mice vs. wild type mice using [18F]FDG total-body PET.","date":"2025","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40470038","citation_count":4,"is_preprint":false},{"pmid":"36540015","id":"PMC_36540015","title":"Increased PHOSPHO1 and alkaline phosphatase expression during the anabolic bone response to intermittent parathyroid hormone delivery.","date":"2022","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/36540015","citation_count":3,"is_preprint":false},{"pmid":"35943680","id":"PMC_35943680","title":"PHOSPHO1 Serves as a Key Metabolism-Related Biomarker in the Tumorigenesis of Diffuse Large B-cell Lymphoma.","date":"2022","source":"Current medical science","url":"https://pubmed.ncbi.nlm.nih.gov/35943680","citation_count":3,"is_preprint":false},{"pmid":"23860651","id":"PMC_23860651","title":"The use of tissue-nonspecific alkaline phosphatase (TNAP) and PHOSPHO1 inhibitors to affect mineralization by cultured cells.","date":"2013","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/23860651","citation_count":2,"is_preprint":false},{"pmid":"40574346","id":"PMC_40574346","title":"Co-overexpression of the caloric restriction-induced mitochondrial factors PGC-1α and MIPEP upregulates Phospho1 expression in adipocytes.","date":"2025","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/40574346","citation_count":1,"is_preprint":false},{"pmid":"32693758","id":"PMC_32693758","title":"PHOSPHO1 Gene DNA Methylations are Associated with a Change in HDL-C Response to Simvastatin Treatment.","date":"2020","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/32693758","citation_count":1,"is_preprint":false},{"pmid":"41664674","id":"PMC_41664674","title":"Methylation analysis of PHOSPHO1 and ACACA gene promoters in whole blood samples: insights into metabolic syndrome and associated factors.","date":"2026","source":"Journal of diabetes and metabolic disorders","url":"https://pubmed.ncbi.nlm.nih.gov/41664674","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19936,"output_tokens":5257,"usd":0.069332},"stage2":{"model":"claude-opus-4-6","input_tokens":8794,"output_tokens":3378,"usd":0.19263},"total_usd":0.261962,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Human PHOSPHO1 exhibits high specific phosphatase activity toward phosphoethanolamine (PEA) and phosphocholine (PCho), with apparent Km values of 3.0 µM for PEA and 11.4 µM for PCho, optimal activity at pH 6.7, and strict Mg2+-dependence, establishing these as its natural substrates and providing a mechanism for inorganic phosphate generation in mineralizing cells.\",\n      \"method\": \"In vitro enzymatic assay with recombinant PHOSPHO1, substrate kinetics, pH and metal ion dependence studies\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic reconstitution with recombinant protein and full kinetic characterization\",\n      \"pmids\": [\"15175005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Comparative modeling of human PHOSPHO1 based on phosphoserine phosphatase (PSP) crystal structure identified a catalytic Mg2+-binding site coordinated by three conserved Asp residues (Asp32, Asp34, Asp203) and revealed that PHOSPHO1 belongs to a novel subgroup within the HAD superfamily distinct from PSPs, with Asp43 and Asp123 proposed to confer substrate specificity.\",\n      \"method\": \"Comparative homology modeling based on Methanococcus jannaschii PSP crystal structure; sequence conservation analysis\",\n      \"journal\": \"Protein engineering\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 structural modeling but without experimental mutagenesis validation in same paper; later validated by mutagenesis in PMID 16054448\",\n      \"pmids\": [\"14983068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Mutagenesis of Asp32 and Asp203 abolished PHOSPHO1 phosphatase activity, confirming HAD superfamily membership and catalytic mechanism; Asp43 and Asp123 mutations impaired substrate hydrolysis, demonstrating their role in substrate binding. PHOSPHO2, despite 42% sequence identity, preferentially hydrolyzes pyridoxal-5-phosphate rather than PEA or PCho.\",\n      \"method\": \"Site-directed mutagenesis of active-site residues; in vitro enzymatic assay with recombinant proteins\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct active-site mutagenesis with enzymatic activity readout\",\n      \"pmids\": [\"16054448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PHOSPHO1 protein is localized by immunohistochemistry specifically to sites of active mineralization in bone and cartilage: osteoid layer of periosteum, forming surfaces of growing osteons, newly formed osteocytes, early hypertrophic chondrocytes of growth plate, and mineralizing surfaces of trabecular bone; absent from non-mineralizing soft tissues.\",\n      \"method\": \"Immunohistochemistry with affinity-purified antibody; RT-PCR in osteoblast cell lines\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization by IHC with functional-context correlation, single lab\",\n      \"pmids\": [\"15050893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PHOSPHO1 is present within matrix vesicles (MVs) isolated from growth plate chondrocytes as confirmed by immunoblotting, and its expression is upregulated in MVs from chondrocytes induced to differentiate, mirroring TNAP activity upregulation; its developmental expression in chick precedes mineralization onset, consistent with an initiating role.\",\n      \"method\": \"Immunoblotting of isolated MVs; whole-mount in situ hybridization; qPCR during chondrocyte differentiation\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct MV fractionation with immunoblot confirmation plus developmental expression timing, replicated across studies\",\n      \"pmids\": [\"16837257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PHOSPHO1 is functionally active within matrix vesicles: sonicated (but not intact) MVs from TNAP-deficient osteoblasts exhibit PEA hydrolase activity attributable to PHOSPHO1, and pharmacological inhibitors of PHOSPHO1 (lansoprazole, SCH202676) reduce MV-mediated mineralization by 56.8% and 70.7%, respectively.\",\n      \"method\": \"Enzyme activity assay in sonicated MVs; high-throughput screening for inhibitors; MV calcification assay in TNAP-null background\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — enzymatic activity in MV fractions plus pharmacological inhibition with functional mineralization readout\",\n      \"pmids\": [\"17227223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Phospho1-/- mice display growth plate abnormalities, spontaneous fractures, bowed long bones, osteomalacia, and scoliosis; Phospho1-/- chondrocyte-derived MVs show reduced mineralizing ability; plasma PPi is elevated. Transgenic TNAP overexpression normalizes PPi but does not rescue the bone phenotype, indicating PHOSPHO1 has a nonredundant, TNAP-independent role in initiating skeletal mineralization. Double ablation of PHOSPHO1 and TNAP completely abolishes skeletal mineralization and causes perinatal lethality.\",\n      \"method\": \"Phospho1-/- knockout mouse; TNAP transgenic overexpression in Phospho1-/- background; double Phospho1/Alpl knockout; primary chondrocyte MV calcification assay; plasma PPi measurement\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic epistasis with double KO, rescue experiment, and in vitro MV assay; replicated across multiple labs\",\n      \"pmids\": [\"20684022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PHOSPHO1 deficiency in MVs reduces ATP hydrolysis kinetics secondarily via reduction in TNAP levels within PHOSPHO1-deficient MVs; kinetic analysis establishes TNAP as the primary enzyme hydrolyzing ATP and PPi within the MV compartment, while PHOSPHO1 affects MV phosphosubstrate hydrolysis indirectly through regulation of TNAP levels.\",\n      \"method\": \"Kinetic substrate hydrolysis assays (ATP, ADP, PPi) on isolated MVs from WT, TNAP-/-, NPP1-/-, and PHOSPHO1-deficient osteoblasts\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinetic reconstitution with genetically defined MV fractions\",\n      \"pmids\": [\"19874193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In vivo inhibition of PHOSPHO1 with lansoprazole completely prevented mineralization of chick limb long bones, and the talpid3 chick mutant (defective hedgehog signaling, absent endochondral mineralization) lacked Phospho1 and Tnap expression, linking hedgehog-regulated chondrocyte differentiation to PHOSPHO1-mediated endochondral mineralization.\",\n      \"method\": \"Lansoprazole pharmacological inhibition in chick embryo in vivo; micromass cultures with PHOSPHO1 inhibitor; talpid3 mutant expression analysis; whole-mount in situ hybridization\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — pharmacological inhibition in vivo plus mutant model with mechanistic pathway context\",\n      \"pmids\": [\"20053388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PHOSPHO1 is expressed and upregulated in mineralizing vascular smooth muscle cells (VSMCs); Phospho1-/- VSMCs fail to mineralize in vitro; pharmacological inhibition of PHOSPHO1 (MLS-0263839) reduces VSMC calcification to ~42% of control, and combined PHOSPHO1 + TNAP inhibition reduces it to ~21%, demonstrating PHOSPHO1 plays a critical initiating role in vascular smooth muscle cell calcification.\",\n      \"method\": \"Phospho1-/- VSMC cultures; PHOSPHO1-specific inhibitors identified by HTS; calcification assay; dual inhibitor experiment\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological inhibition with quantitative calcification readout\",\n      \"pmids\": [\"22887744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Phospho1-/- mice have elevated plasma osteopontin (OPN) with increased proportion of phosphorylated OPN (p-OPN) in skeleton as shown by LC-MS/MS; genetic ablation of Spp1 (OPN) in Phospho1-/- mice ameliorates scoliosis and long bone defects and corrects mineralization in vitro, identifying p-OPN accumulation (not elevated PPi) as the primary driver of the skeletal phenotype in PHOSPHO1 deficiency.\",\n      \"method\": \"LC-MS/MS phosphoproteomic analysis; double Phospho1-/-/Spp1-/- knockout mice; histology; in vitro mineralization assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic epistasis double KO with rescue plus LC-MS/MS mechanistic identification\",\n      \"pmids\": [\"24825455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Double knockout of Phospho1 and Pit1 (phosphate transporter Slc20a1 in chondrocytes) causes more severe skeletal mineralization defects than Phospho1-/- alone; ~80% of double-KO MVs lack mineral vs ~50% for Phospho1-/- and ~25% for WT, measured by atomic force microscopy. Phospho1-/- and double-KO chondrocytes also produce fewer MVs, implicating PHOSPHO1 in MV biogenesis.\",\n      \"method\": \"Conditional double knockout (Phospho1-/- ; Pit1col2/col2); atomic force microscopy of MVs; bone histomorphometry; biomechanical testing\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic epistasis double KO with quantitative MV mineral content by AFM\",\n      \"pmids\": [\"26773408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PTH-induced downregulation of PHOSPHO1 expression in osteoblasts is mediated through the cAMP/PKA signaling pathway, as demonstrated by mimicry with the cAMP agonist forskolin and blockade by PKA inhibitor PKI(5-24); PTH also coordinately suppresses nSMase2 (Smpd3) expression.\",\n      \"method\": \"Pharmacological pathway dissection (forskolin, PKA inhibitor PKI 5-24) in MC3T3-C14 osteoblast cultures; qPCR; hemi-calvaria organ culture\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis with agonist/antagonist pair identifying cAMP/PKA pathway, single lab\",\n      \"pmids\": [\"27444010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In Phospho1-/- mice, PHOSPHO1 loss leads to defects in alveolar bone and cellular cementum mineralization (cementoid accumulation, interglobular mineral deposition) with increased OPN deposition; acellular cementum is unaffected, indicating acellular cementum mineralization does not depend on matrix vesicle-mediated (PHOSPHO1-driven) initiation.\",\n      \"method\": \"Phospho1-/- mouse histology, immunohistochemistry, ISH, microCT; comparison of cellular vs acellular cementum phenotypes\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with specific phenotypic dissection of two mineralization pathways\",\n      \"pmids\": [\"27016531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PHOSPHO1 is localized to ameloblast secretory vesicles and the enamel layer; Phospho1-/- mice show reduced enamel mineralization (2-fold reduction in von Kossa silver grain density), decreased phosphate incorporation by EDS, loss of enamel prism architecture, and 1.56-fold increase in prism width, establishing PHOSPHO1 as essential for enamel mineralization.\",\n      \"method\": \"Immunohistochemistry; Western blot; Phospho1-/- mouse; scanning electron microscopy; EDS elemental analysis; von Kossa staining\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with multiple orthogonal readouts (SEM, elemental analysis, histology), single lab\",\n      \"pmids\": [\"29089903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PHOSPHO1 negatively regulates brown adipose tissue (BAT) thermogenesis: Phospho1-/- mice are cold-tolerant with higher thermogenic gene expression in BAT; treatment of mice with the PHOSPHO1 substrate phosphocholine is sufficient to induce cold tolerance and thermogenic gene expression, demonstrating the phosphocholine-to-choline conversion catalyzed by PHOSPHO1 suppresses BAT thermogenesis.\",\n      \"method\": \"Phospho1-/- mouse; cold tolerance assay; thermogenic gene expression (qPCR); exogenous phosphocholine treatment in vivo\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO phenotype plus substrate supplementation rescue experiment, establishing causal substrate-product relationship\",\n      \"pmids\": [\"32554489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Phospho1-/- mice exhibit improved glucose homeostasis and resistance to high-fat diet-induced obesity and insulin resistance independent of osteocalcin; decreased serum choline in Phospho1-/- mice is normalized by 2% dietary choline supplementation, which also normalizes insulin sensitivity and fat mass, linking PHOSPHO1's phosphocholine hydrolysis activity to systemic choline levels and metabolic regulation.\",\n      \"method\": \"Phospho1-/- mouse; high-fat diet challenge; metabolomics (serum choline); dietary choline rescue experiment; osteoblast transcriptomics\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO plus dietary rescue experiment linking enzymatic product (choline) to metabolic phenotype\",\n      \"pmids\": [\"33092598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Proton pump inhibitors (PPIs) directly inhibit PHOSPHO1 enzymatic activity in vitro (IC50 0.73–19.27 µM for different PPIs) and inhibit bone matrix mineralization in primary osteoblast cultures in a concentration-dependent manner; H2 receptor antagonists have no inhibitory effect on PHOSPHO1, suggesting PPI-specific inhibition.\",\n      \"method\": \"In vitro PHOSPHO1 enzymatic activity assay with PPIs; primary osteoblast mineralization assay\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic inhibition with IC50 determination plus cell-based mineralization assay, single lab\",\n      \"pmids\": [\"34213594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PHOSPHO1 (cytosolic protein) exhibits D609-sensitive phosphatidylcholine-phospholipase C (PC-PLC) and phosphatidylethanolamine-phospholipase C (PE-PLC) activities in vitro; overexpression in HEK293 cells increases cellular diacylglycerol (DG) levels; PHOSPHO1 co-sediments and co-localizes with diacylglycerol kinase δ (DGKδ), suggesting PHOSPHO1 supplies DG upstream of DGKδ.\",\n      \"method\": \"In vitro PLC activity assay; HEK293 overexpression with DG lipid measurement; co-sedimentation and co-localization assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzymatic activity plus cell-based overexpression and co-localization, single lab, novel finding\",\n      \"pmids\": [\"39992810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A novel alternatively spliced PHOSPHO1 transcript (PHOSPHO1-3a) was identified, encoding a 292 amino acid protein with a 40 amino acid N-terminal secretory signal while retaining all three HAD superfamily catalytic domains; expression confirmed in human and mouse osteoblast-like cells and chondrogenic ATDC5 cells.\",\n      \"method\": \"RT-PCR; sequence analysis; in silico signal peptide prediction; cell-line expression profiling\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — transcript identification without functional validation of the splice variant protein\",\n      \"pmids\": [\"18471996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Lansoprazole acts as an efficient inhibitor of adipose PHOSPHO1 and produces metabolic benefits (reduced obesity, improved insulin resistance) in a PHOSPHO1-dependent manner; mechanistically, LPZ inhibition of PHOSPHO1 is proposed to suppress conversion of 2-AG-LPA to 2-AG, reducing thermogenic-suppressive cannabinoid receptor signaling.\",\n      \"method\": \"PHOSPHO1 enzymatic inhibition assay; Phospho1-/- mouse rescue/dependency experiment; adipocyte thermogenesis and mitochondrial respiration assays\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic inhibition confirmed plus PHOSPHO1-dependent in vivo metabolic effects, with proposed substrate mechanism\",\n      \"pmids\": [\"38572109\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PHOSPHO1 is a Mg2+-dependent HAD-superfamily phosphatase that hydrolyzes phosphoethanolamine and phosphocholine (and exhibits phospholipase C activity on PC/PE) within matrix vesicles to generate inorganic phosphate for the initiation of hydroxyapatite crystal nucleation during skeletal, dental, and vascular mineralization, acting nonredundantly with TNAP (whose role is extravesicular PPi hydrolysis); beyond mineralization, PHOSPHO1's hydrolysis of phosphocholine to choline regulates systemic choline levels and negatively modulates brown adipose tissue thermogenesis and whole-body glucose/fat metabolism.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PHOSPHO1 is a Mg2+-dependent HAD-superfamily phosphatase that generates inorganic phosphate within matrix vesicles by hydrolyzing phosphoethanolamine and phosphocholine, thereby initiating hydroxyapatite crystal nucleation during skeletal, dental, and vascular mineralization. Catalytic activity depends on conserved aspartate residues (Asp32, Asp203) for phosphoryl transfer and Asp43/Asp123 for substrate binding [PMID:15175005, PMID:16054448], and PHOSPHO1 operates nonredundantly with tissue-nonspecific alkaline phosphatase (TNAP): double ablation of Phospho1 and Alpl abolishes skeletal mineralization and causes perinatal lethality, whereas TNAP overexpression cannot rescue the Phospho1-null bone phenotype [PMID:20684022]. The mineralization defect in Phospho1-/- mice is driven primarily by accumulation of phosphorylated osteopontin rather than elevated PPi, as genetic removal of Spp1 ameliorates the skeletal phenotype [PMID:24825455]. Beyond mineralization, PHOSPHO1's hydrolysis of phosphocholine to choline regulates systemic choline levels, and its loss confers resistance to diet-induced obesity, improved glucose homeostasis, and enhanced brown adipose tissue thermogenesis—phenotypes reversed by dietary choline supplementation [PMID:33092598, PMID:32554489].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Structural modeling placed PHOSPHO1 within the HAD superfamily and identified candidate catalytic and substrate-specificity residues, providing the first framework for understanding its enzymatic mechanism.\",\n      \"evidence\": \"Comparative homology modeling based on Methanococcus jannaschii phosphoserine phosphatase crystal structure\",\n      \"pmids\": [\"14983068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Model-based predictions lacked experimental mutagenesis validation at time of publication\", \"No crystal structure of PHOSPHO1 itself\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Kinetic characterization established phosphoethanolamine and phosphocholine as high-affinity natural substrates and defined the strict Mg2+ dependence, answering the fundamental question of what PHOSPHO1 hydrolyzes and how it generates inorganic phosphate.\",\n      \"evidence\": \"In vitro enzymatic assay with recombinant PHOSPHO1; substrate kinetics, pH and metal ion dependence\",\n      \"pmids\": [\"15175005\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo substrate utilization within matrix vesicles not yet demonstrated\", \"Product (Pi) contribution to mineral nucleation not directly shown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Immunolocalization of PHOSPHO1 protein exclusively to sites of active mineralization in bone and cartilage established the physiological context for its enzymatic activity.\",\n      \"evidence\": \"Immunohistochemistry with affinity-purified antibody on developing bone and growth plate sections\",\n      \"pmids\": [\"15050893\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab IHC study\", \"Sub-cellular localization to matrix vesicles not shown in this study\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Site-directed mutagenesis confirmed the HAD-superfamily catalytic mechanism by showing Asp32 and Asp203 are essential for activity and Asp43/Asp123 mediate substrate binding, validating the earlier structural model.\",\n      \"evidence\": \"Site-directed mutagenesis of active-site residues with in vitro enzymatic assay\",\n      \"pmids\": [\"16054448\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure to visualize substrate-binding geometry\", \"Distinction between PEA and PCho binding determinants not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Direct immunoblot detection of PHOSPHO1 within isolated matrix vesicles and its upregulation during chondrocyte differentiation answered where within the extracellular space PHOSPHO1 acts and linked its expression to the onset of mineralization.\",\n      \"evidence\": \"MV fractionation with immunoblotting; whole-mount in situ hybridization in developing chick\",\n      \"pmids\": [\"16837257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic activity within intact MVs not yet demonstrated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating PHOSPHO1 enzymatic activity within matrix vesicles and showing that pharmacological PHOSPHO1 inhibition reduces MV-mediated mineralization established PHOSPHO1 as a functional mineralizing enzyme inside MVs, not merely a co-localized protein.\",\n      \"evidence\": \"PEA hydrolase activity in sonicated MVs from TNAP-null osteoblasts; HTS-derived inhibitors (lansoprazole, SCH202676); MV calcification assay\",\n      \"pmids\": [\"17227223\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitor specificity for PHOSPHO1 over other phosphatases not fully characterized\", \"Activity measured in sonicated, not intact, MVs\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Genetic epistasis experiments using Phospho1-/-, TNAP transgenic rescue, and double Phospho1/Alpl knockout mice established that PHOSPHO1 has a nonredundant, TNAP-independent role in initiating mineralization, resolving the long-standing question of whether MV-intrinsic and extravesicular Pi-generating pathways are functionally separable.\",\n      \"evidence\": \"Phospho1-/- knockout; TNAP transgenic overexpression in Phospho1-/- background; double knockout causing perinatal lethality; MV calcification assay; plasma PPi measurement\",\n      \"pmids\": [\"20684022\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise molecular product (Pi vs membrane lipid remodeling) driving mineral nucleation not distinguished\", \"Human genetic validation lacking\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"In vivo pharmacological inhibition of PHOSPHO1 with lansoprazole completely prevented long bone mineralization in chick embryos, confirming the in vivo requirement and linking hedgehog-regulated chondrocyte differentiation upstream of PHOSPHO1 expression.\",\n      \"evidence\": \"Lansoprazole treatment of chick embryos; talpid3 hedgehog mutant expression analysis\",\n      \"pmids\": [\"20053388\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lansoprazole has off-target effects (proton pump); specificity for PHOSPHO1 in vivo uncertain\", \"Hedgehog–PHOSPHO1 transcriptional pathway intermediates not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of phosphorylated osteopontin accumulation—rather than elevated PPi—as the primary driver of the Phospho1-/- skeletal phenotype reframed the mechanism: PHOSPHO1 loss permits p-OPN to inhibit mineralization, and genetic removal of Spp1 rescues the defect.\",\n      \"evidence\": \"LC-MS/MS phosphoproteomics; double Phospho1-/-/Spp1-/- knockout with phenotypic rescue\",\n      \"pmids\": [\"24825455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PHOSPHO1 directly dephosphorylates OPN or acts indirectly not resolved\", \"Contribution of PPi versus p-OPN in vivo not fully quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genetic interaction between Phospho1 and Pit1 (Slc20a1) revealed that PHOSPHO1-generated Pi and transporter-imported Pi act in parallel to load MVs with mineral; PHOSPHO1 deficiency also reduced MV number, suggesting an additional role in MV biogenesis.\",\n      \"evidence\": \"Conditional Phospho1-/-;Pit1col2/col2 double knockout; atomic force microscopy of MVs; bone histomorphometry\",\n      \"pmids\": [\"26773408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which PHOSPHO1 influences MV biogenesis unknown\", \"Whether MV membrane lipid remodeling links phospholipid hydrolysis to budding not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extension of PHOSPHO1's role to dental tissues showed it is required for alveolar bone and cellular cementum mineralization but dispensable for acellular cementum, distinguishing MV-dependent from MV-independent mineralization pathways in teeth.\",\n      \"evidence\": \"Phospho1-/- mouse dental histology, IHC, ISH, microCT\",\n      \"pmids\": [\"27016531\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis for why acellular cementum is PHOSPHO1-independent not explained\", \"Single-lab observation\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery that Phospho1-/- mice are resistant to diet-induced obesity with improved insulin sensitivity, and that dietary choline supplementation normalizes these phenotypes, established a systemic metabolic function for PHOSPHO1 through its phosphocholine-to-choline conversion activity.\",\n      \"evidence\": \"Phospho1-/- mouse on high-fat diet; serum metabolomics (choline); dietary choline rescue\",\n      \"pmids\": [\"33092598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue source of metabolically relevant PHOSPHO1 activity (bone vs adipose vs other) not delineated\", \"Direct measurement of phosphocholine/choline flux in specific tissues lacking\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstration that phosphocholine supplementation alone induces cold tolerance and thermogenic gene expression established that PHOSPHO1's substrate phosphocholine, not its product choline, drives brown adipose tissue activation—resolving the directionality of the metabolic effect.\",\n      \"evidence\": \"Phospho1-/- mouse cold tolerance assay; exogenous phosphocholine treatment in vivo; BAT thermogenic gene expression\",\n      \"pmids\": [\"32554489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct sensor/receptor for phosphocholine in BAT not identified\", \"Whether this is a cell-autonomous or systemic (endocrine) effect not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of phospholipase C activity on phosphatidylcholine and phosphatidylethanolamine, with diacylglycerol production and co-localization with DGKδ, expanded PHOSPHO1's substrate repertoire beyond soluble phosphomonoesters to intact phospholipids.\",\n      \"evidence\": \"In vitro PLC activity assay; HEK293 overexpression with DG lipid measurement; co-sedimentation and co-localization with DGKδ\",\n      \"pmids\": [\"39992810\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of PLC activity relative to PEA/PCho hydrolysis not established\", \"Single-lab finding awaiting independent confirmation\", \"Functional consequence of PHOSPHO1-DGKδ coupling not tested in mineralizing cells\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the crystal structure of PHOSPHO1, the identity of the tissue(s) and cell type(s) responsible for its systemic metabolic effects, whether its phospholipase C activity contributes to MV membrane remodeling and biogenesis, and whether human PHOSPHO1 loss-of-function mutations cause a recognizable skeletal or metabolic disease.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure available\", \"No human genetic disease association from direct evidence\", \"Relative contribution of PEA/PCho hydrolysis versus PLC activity in vivo unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 5, 7]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4, 5, 14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 15, 16, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 8, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ALPL\",\n      \"SPP1\",\n      \"SLC20A1\",\n      \"DGKD\",\n      \"SMPD3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}